car-t cell therapy safety monitoring
Stop Using Chronic Disease Management - Do This for CAR‑T
87% of emerging cytokine release syndrome signals were intercepted within two hours using CASTLE’s real-time monitoring, proving that a targeted safety scaffold beats generic chronic-disease protocols. The trial showed that integrating chronic-care tools into CAR-T studies can keep patients safe while preserving therapeutic potency. This approach reshapes how we